Pila Pharma Starts Safety Part of Obesity Trial PP-CT04
Pila Pharma AB (publ) has enrolled the first subject in Part 1 (safety) of PP-CT04, a 12-week randomized, double-blind, placebo-controlled trial of XEN-D0501 in obesity.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Pila Pharma starts enrollment for PP-CT04 Part 1 obesity trial of XEN-D0501
Pila Pharma initiated its first clinical site for PP-CT04, enabling enrollment to begin in Part 1 of a 12-week obesity trial testing oral TRPV1 antagonist XEN-D0501. Part 1 enrolls 8 participants to generate initial safety findings before Part 2 can start.
PILA PHARMA AB (publ) (PILA) Starts Enrollment for 8-Patient Safety Cohort in 12-Week Obesity Trial
PILA PHARMA AB (publ) initiated and activated its first site and began enrollment for Part 1 (8 participants) of PP-CT04, a 12—week, randomized, placebo—controlled trial of XEN—D0501 in obesity. Part 2 may start after ≥5 weeks dosing in Part 1 and a favorable safety review.Material DetailsContext b…